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Abstract
Background: Bone marrow mesenchymal stem cells (MSCs) are one of the potential tools for
treatment of the spinal cord injury; however, the survival and differentiation of MSCs in an injured
spinal cord still need to be improved. In the present study, we investigated whether Governor Vessel
electro-acupuncture (EA) could efficiently promote bone marrow mesenchymal stem cells (MSCs)
survival and differentiation, axonal regeneration and finally, functional recovery in the transected
spinal cord.
Results: The spinal cords of adult Sprague-Dawley (SD) rats were completely transected at T10,
five experimental groups were performed: 1. sham operated control (Sham-control); 2. operated
control (Op-control); 3. electro-acupuncture treatment (EA); 4. MSCs transplantation (MSCs); and
5. MSCs transplantation combined with electro-acupuncture (MSCs+EA). After 2-8 weeks of MSCs
transplantation plus EA treatment, we found that the neurotrophin-3 (NT-3), cAMP level, the
differentiation of MSCs, the 5-HT positive and CGRP positive nerve fibers in the lesion site and
nearby tissue of injured spinal cord were significantly increased in the MSCs+EA group as compared
to the group of the MSCs transplantation or the EA treated alone. Furthermore, behavioral test
and spinal cord evoked potentials detection demonstrated a significantly functional recovery in the
MSCs +EA group.
Conclusion: These results suggest that EA treatment may promote grafted MSCs survival and
differentiation; MSCs transplantation combined with EA treatment could promote axonal
regeneration and partial locomotor functional recovery in the transected spinal cord in rats and
indicate a promising avenue of treatment of spinal cord injury.
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Background
Functional deficits following spinal cord injury (SCI)
result from neuronal damage, demyelination of axons,
and dysfunctional neuroglial cells. The failure of axonal
regeneration following SCI has been attributed to a non-
permissive environment containing inflammatory media-
tors, lack of neurotrophic support, and inhibitory mole-
cules. Numerous therapeutic strategies attempt to
overcome these negative factors and promote axon regen-
eration, including transplanting tissue bridges [1,2], artifi-
cial scaffolds [3,4], cellular transplants of various cells
types [5-11], growth factors [12,13], and various combi-
natorial treatments [14-18]. However, at present, there
still is a lack of effective treatments for spinal cord injuries.
Previously, we reported that co-implanting Schwann cells
and neural stem cells (NSCs) into a semi-transected or
completely transected spinal cord significantly affected its
recovery under certain circumstances [19,20]. However,
neural stem cells face limitations inherent in their pro-
curement from fetal tissue, including histocompatibility
and ethical concerns for clinical use. Bone marrow mesen-
chymal stem cells (MSCs) have been suggested as an alter-
ative in spinal cord injury research and a promising
candidate for the treatment of central nervous system
injuries [21,22]. Potential advantages of MSCs over other
types of transplanted cells include their ability to be har-
vested from autologous donors, their relatively rapid
expansion in vitro, and the possibility that allogeneic
MSCs are not immunogenic and hence, readily available
for clinical use [21]. MSCs also secrete a variety of growth
factors and cytokines that could contribute to reparation
after a CNS injury [23-25]. Studies have suggested that
MSCs can differentiate into neural phenotypes [26-31],
which would enable them to replace lost neural cells after
a brain or spinal cord injury. However, the limitations of
MSCs include their poor survival and differentiation into
neurons when transplanted into injured spinal cord
[22,32,33].
Acupuncture is a therapeutic technique used in traditional
Chinese medicine. Since its development several thou-
sand years ago, acupuncture has made many contribu-
tions to healthcare and medical treatment. Electro-
acupuncture (EA) is a type of therapy in which a needle
inserted into an acupoint is attached to a trace pulse cur-
rent with the purpose of producing synthetic electric and
needling stimulation. The application of EA for the treat-
ment of SCI has shown promising results in the allevia-
tion of the patients' suffering [34]. EA is used on 'Governor
Vessel' acupoints for the treatment of spinal cord injury
because the impairment of this channel is regarded as the
essence of spinal cord damage in traditional Chinese med-
icine. The use of EA on the Governor Vessel has been shown
to alleviate secondary damage after a spinal cord injury in
both patients and animal models [35,36]. Interestingly,
our previous study found that utilizing EA on the Governor
Vessel promotes NT-3 secretion in the injured spinal cord
and enhances the differentiation of grafted neural stem
cells (NSCs) into neuron-like cells in the injured site [37].
Furthermore, the combination of Governor Vessel EA and
NSCs transplantation promotes axonal regeneration and
improves function in completely transected spinal cords
of rats [38,39]. In this study, we investigated whether the
transplantation of MSCs, combined with EA treatment
could stimulate and promote survival and differentiation
of transplanted MSCs, axonal regeneration, and func-
tional improvement of the injured spinal cord.
Methods
Preparation of bone marrow mesenchymal stem cells 
(MSCs)
MSCs were prepared from one-month-old Sprague-Daw-
ley (SD) rats in accordance with the procedure described
in detail in our previous study [31]. The tibias and femurs
of the SD rats were dissected under anesthesia and aseptic
conditions. After removing the end of the bone, 5 ml of
Dulbecco's modified Eagle medium (DMEM, Gibco/BRL,
Carlsbad, CA) was injected into the central canal of the
bone to extrude the bone marrow. The solution contain-
ing bone marrow was then centrifuged at 1000 rpm for 5
min. The pellet was resuspended in DMEM and supple-
mented with 10% inactivated fetal bovine serum (FBS),
penicillin (100 U/ml), and streptomycin (100 mg/ml).
The cells were then cultured in a 75 ml cell flask and after
plating the cells for 48 h, the medium was replaced to
remove non-adherent cells. When the adherent MSCs
grew to near confluency, they were serially passaged using
0.25% trypsin/0.02% EDTA. After being passaged 3–5
times, the MSCs were ready for use in transplantation.
To verify the survival and transdifferentiation of trans-
planted MSCs, third or fourth generation MSCs were
labeled with bromodeoxyuridine (BrdU, 1 μmol/L,
Sigma) and Bisbenzimide (Hoechst33342, 10 μg/1 ml,
Sigma). Two days before transplantation, MSCs were
treated with 1 μmol/L BrdU for 48 h. In addition, MSCs
were labeled with blue nuclear fluorescence Hoechst
33342 (10 μg/1 ml) 2 h before transplantation. Next, the
MSCs were washed 3 times with D-Hank's balanced salt
solution (HBSS, pH 7.4), and removed from the culture
flasks using 0.25% trypsin/0.02% EDTA (Sigma). MSCs
were centrifuged and resuspended in DMEM medium for
cell counting. After undergoing the trypan blue dye exclu-
sion test, the cell suspension was adjusted to a final con-
centration of 1×105 viable cells/μl in culture medium for
transplantation.
Animal groups and spinal cord surgery
Experiments were performed on 66 adult female SD rats
(Experimental Animal Center, Zhongshan School of Med-
icine of Sun Yat-sen University, China) weighing 230~250BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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g. Rats were housed in a temperature-controlled (24 ±
2°C) and light-controlled (12:12 light-dark cycle) room
with free access to food and water. Prior to experimental
manipulation, rats were allowed to acclimate to the hous-
ing facilities and were handled daily at least for 3 days. All
experimental protocols and animal handling procedures
were approved by the Animal Care and Use Committee of
Sun Yat-sen University, and were consistent with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
The rats were divided into 5 groups. The first group, the
sham-control group, received only a laminectomy (Sham-
control). The remaining four groups underwent complete
transections at the T10 spinal segment of the spinal cord
as follows: the Op-control group received a spinal cord
transection only; the EA group received EA treatment after
the spinal cord transection; the MSCs group received
MSCs transplantation after spinal cord transection; and
the MSCs+EA group received transplanted MSCs with EA
treatment after transection.
T9–T10 laminectomy: Briefly, the animals were anesthe-
tized with 1% sodium pentobarbital (40 mg/kg, i.p.). A
laminectomy was carried out at the T9-T10 level to expose
the T10 spinal segment. The dura was cut and the T10 seg-
ment was transected completely with a scalpel with no tis-
sue removed [40,41]. A complete transection of the spinal
cord was verified histologically. In the Op-control and EA
groups, a piece of gelfoam (2 × 2 × 2 mm3, preinjected
DMEM 5 μl) was inserted into the lesion site. In the MSCs
and MSCs+EA groups, a small piece of gelfoam, which
was preinjected with a MSCs suspension (1 × 105 cells/μl,
5 μl), was placed into the transected site of the spinal cord.
After surgery and gelfoam transplantion, the dura was
sutured, and the muscle and skin were closed in layers. In
the sham-control group, rats received a laminectomy
without any further spinal cord damage. After surgery, all
rats received an intramuscular injection of penicillin
(160,000 U/ml/d) and were housed separately in individ-
ual cages with thick soft bedding. Manual emptying of the
bladders was performed twice daily. In the EA and
MSCs+EA groups, rats received EA treatment every other
day, beginning the seventh day post-spinal cord transec-
tion for a total of 7 weeks.
Electro-acupuncture treatment
Two pairs of 'Governor Vessel' acupoints were utilized dur-
ing EA treatment. One pair of acupoints is Changqiang
(GV1) and Yaoshu (GV2); another pair of acupoints is
Jizhong (GV6) and Zhiyang (GV9) (Fig. 1). The acupoint
GV1 is located at the midpoint between the tip of the coc-
cyx and the anus in prone position. GV2 is located on the
posterior midline and in the hiatus of the sacrum in prone
position. The acupoint GV6 is located on the posterior
midline and in the depression below the spinous process
of the eleventh thoracic vertebra in prone position. GV9 is
located on the posterior midline and in the depression
below the spinous process of the seventh thoracic vertebra
in prone position. GV6 and GV9 are located on the
depression below the rostral and caudal spinous process
of transected spinal cord, respectively. EA on both GV6
and GV9 acupoints can directly treat the injured spinal
cord. EA on both the GV1 and GV2 acupoints can improve
emptying the bowels and bladder and lumbar vertebrae
pain.
Rats were loosely immobilized in a specially made
restrainer that exposed their dorsal spine, hind legs, and
tails. Two pairs of stainless silver needles of 0.3 mm in
diameter were inserted into the GV1 and GV2, and GV6
and GV9, to a depth of 5 mm. The two pairs of needles
were connected to the output terminals of an electro-acu-
puncture apparatus (Model G 6805-2, Shanghai Medical
Electronic Apparatus Company, China). Alternating
strings of dense-sparse frequencies (60 Hz for 1.05 s and
2 Hz for 2.85 s) were used. The intensity was adjusted to
induce a slight twitch of the hindlimb (≤ 1 mA) and lasted
for 20 min. EA was administered once every other day for
7 weeks, starting from the seventh day post-surgery.
cAMP and NT-3 assay
In accordance with our previous work [39], cAMP levels
were detected 2 weeks after the spinal cord transection.
Sixteen rats (N = 4 for each group) were anesthetized with
1% sodium pentobarbital (40 mg/kg) and transcardially
perfused with 200 ml of ice-cold 0.1 M PB. Subsequently,
a 1 cm long segment of T9–10 spinal cord containing the
lesion site was quickly removed and dissected on dry ice.
The segments were weighed and permeabilized with ice-
Schematic diagram indicates the four selected acupoints of  the 'Governor vessel' Figure 1
Schematic diagram indicates the four selected acu-
points of the 'Governor vessel'. Changqiang (GV1), 
Yaoshu (GV2), Jizhong (GV6), and Zhiyang (GV9), which cor-
respond to equivalent acupoints in humans.BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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cold ethanol. The extracts were lyophilized in a speed vac-
uum (SC110A, Savant Industries, Farmingdale, NY) and
stored at -70°C until analysis. The acetylation protocol
was used to increase the signal strength of cAMP [42]. The
extracts were solubilized in assay buffer then diluted in a
mixture of one part acetic anhydride to two parts triethyl-
amine. A cyclic AMP binding compound, 3', 5'-cyclic
phosphoric acid 2'-0-succinyl-3-[125I]-iodotyrosine
methyl ester, was added to the solution, followed by the
anti-cAMP antiserum. After incubation for 15~18 h at
4°C, Amerlex-M secondary antibody was added to the
sample, and the precipitate was obtained by centrifuga-
tion. An autosampling gamma scintillation counter
(Beckman, Fullerton, CA) counted each sample for 60 s
and the cAMP values were obtained using a standard
curve.
Previously, we tested the NT-3 level 2 weeks after the spi-
nal cord transection and found the NT-3 level increased
after EA treatment [37]. In the present study, we investi-
gated whether EA treatment could maintain the higher
level of NT-3 in the lesion site for a sustained period fol-
lowing the spinal cord injury. Therefore, we decided to
detect the NT-3 level four weeks after the spinal cord
transection. Four weeks after transection of the spinal
cord, 19 rats (N = 4 for each group, except sham control =
3) were anesthetized with 1% sodium pentobarbital (40
mg/kg) and transcardially perfused with 200 ml of ice-
cold 0.1 M PB. Three spinal cord segments, the lesion site
and the areas 1 cm rostral and 1 cm caudal to the lesion
site, were excised while on dry ice. The segments were
weighed and then mechanically homogenized in ice-cold
0.1 M PB. Homogenates were centrifuged for 10 min at
14,000 rpm at 4°C and used for NT-3 ELISA according to
the instructions of the manufacturer (NT-3 Emax Immu-
noAssay System; Boster).
Behavioral analysis
Both the BBB locomotor rating scale and inclined-grid
climbing test were used to analyze the post-surgical motor
behavior of the subjects' hindlimbs [20,43]. The first test
quantitatively evaluates voluntary hindlimb movement
and body weight support. The open field locomotor activ-
ity score was determined by observation and scoring of
behaviors involving the trunk, tail, and hindlimbs. Each
session lasted 4 minutes. Scores from both examiners
were averaged for each rat. Scores ranged from 0 to 21 (0,
no movement; 21, normal movement). The second test
qualitatively assesses accuracy of foot placement and
coordination, which differentiates local reflex activity
from voluntary movement. All animals underwent behav-
ioral testing every 2 weeks post-surgery for 8 weeks. The
tests were videotaped and both examiners were blind to
each group when they participated in behavioral evalua-
tion.
Spinal cord evoked potentials (SCEP)
8 weeks after the spinal cord surgery, 23 rats (N = 5 in each
group except sham control group = 3) were anesthetized
with ketamine (40 mg/kg) and 1% sodium pentobarbital
(30 mg/kg) and stereotaxically fixed. T1-L1 vertebrae were
completely exposed. Briefly, The stimulation electrode
was inserted into the T1-T2 interspinous ligaments, and a
pair of needle electrodes was inserted into the inter-
spinous ligaments of T12 to L1 for SCEP recording,
according to a previous study [44]. The electrodes were
then connected to the BL-410E Data Acquisition Analysis
System for Life Science (Taimeng, China). The Parameter
Settings of the SCEP signal are as follows: gain parameter
2000, time constant 0.01s, filtering 300 Hz. To elicit a
SCEP, a single pulse stimulation, 50 ms in duration at a
frequency of 5.1 Hz and with a 1 mV voltage density, was
transmitted through the electrodes. The voltage density
was set so that it elicited a mild twitch of the animal's ver-
tebral body. In order to obtain high-quality waveforms for
the SCEP signals, 100 SCEP responses were averaged for
each rat. After performing evoked potentials on all sub-
jects, the spinal cords were retransected to investigate
whether the evoked potentials vanished.
Immunohistochemical staining
Following the behavioral testing and evoked potentials
recording, 23 rats of 5 groups were perfused by 4% para-
formaldehyde in phosphate buffer (pH 7.4). Spinal cords
were removed, post-fixed overnight in the paraformalde-
hyde, and cryoprotected in 0.1 M PB containing 30%
sucrose at 4°C. Longitudinal cryosections (25 μm thick-
ness) of spinal cord were cut and mounted on gelatin-
coated slides for immunostaining. Primary antibodies
were used as follows: mouse anti-oligodendrocyte special
protein (clone CE-1, alternate name: MOSP, 1:1000,
Chemicon); mouse anti-ED1 (a mouse monoclonal IgG,
1:200, Serotec, Indianapolis, IN); mouse anti-postsynap-
tic density (95 KDA) protein (PSD-95, 1:200, Sigma); rab-
bit polyclonal anti-serotonin (5-HT, 1:200, Sigma); rabbit
polyclonal anti-calcitonin gene-related peptide (CGRP,
1:8000, Chemicon); rabbit polyclonal anti-glial fibrillary
acidic protein (GFAP, 1:80, Sigma); rabbit polyclonal
anti-synapsin I (1:500, Chemicon); rabbit polyclonal
anti-neurofilament 150 KD (NF150, 1:400, Chemicon);
rabbit polyclonal anti-β-tubulin III (1:100, Sigma). Cy3-
conjugated goat anti-mouse IgG and Cy3-conjugated rab-
bit anti-goat IgG (1:800, Jackson Immunoresearch Labs,
Inc.), FITC-conjugated goat anti-mouse IgG and FITC-
conjugated goat anti-rabbit IgG (1:200, Jackson Immu-
noresearch Labs, Inc.) were used as secondary antibodies.
Sections were washed three times with PBS and incubated
with 10% normal goat serum with 0.3% Triton X-100 in
PBS for 30 min at room temperature. Incubations with
appropriate primary antibodies were performed overnight
at 4°C. After repeated washing with PBS, sections wereBMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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incubated with their respective secondary antibodies for 1
h at 37°C, washed with PBS, coverslipped, and examined
under the fluorescence microscope.
Immunofluorescence double-labeling was performed to
assess the survival and differentiation of transplanted
MSCs. BrdU-labeled transplanted MSCs were identified
by a mouse anti-BrdU antibody and visualized with FITC-
conjugated goat secondary antibodies. Rabbit polyclonal
anti-NF150 (for neurons) or rabbit polyclonal anti-β-
tubulin III (for newly differentiated neurons) were used to
identify the surviving MSCs that had differentiated into
neurons.
A surviving cell count was conducted in 10 longitudinal
spinal cord sections dissecting each animal's injury site, as
a preceding study reported [19]. The surviving MSCs
(labeled by BrdU) were counted in 3 randomly selected
unit areas (0.09 mm2), delineated by a calibrated reticle
eyepiece, distributed throughout the lesion site of each
section. The average number of BrdU-labeled cells from
the unit areas was designated surviving cells and used for
comparison. Differentiated neuron-like cells and oli-
godendrocyte-like cells were also counted in the unit areas
and expressed as a percentage of total surviving engrafted
cells for use in comparison analysis.
Quantitative analysis of 5-HT and CGRP positive nerve
fibers was performed according to prior studies [17,45]. A
calibrated reticle eyepiece was used to delineate regions
300 μm rostral to the transection site, at the transection
site, and 300 μm caudal to the transection site (see Addi-
tional file 1: PDF1 for a sketch of the injured spinal cord
used to clarify the location of quantification). The 5-HT-
labeled nerve fiber profiles were quantified in all regions
at 200 × magnification, while the CGRP-positive fibers
were quantified only in the lesion site at 200 × magnifica-
tion. The spinal cords were cut in longitudinal sections,
and every 5th section was mounted on a gelatin-coated
slide. Ten sections per rat were analyzed and the total
number of labeled fibers in all regions of each experimen-
tal group was averaged. The 5-HT or CGRP-positive fibers
longer than 50 μm were counted as positive fibers.
Data analysis
The total surviving MSCs and the percentages of differen-
tiated cells were compared statistically between the
MSCs+EA and MSCs groups using the Independent Sam-
ples T test. Other data were analyzed using one-way
ANOVA or repeated-measure ANOVA. If equal variances
were found, Fisher's least significant difference test was
performed. Otherwise, the Kruskal-Wallis Test and Dun-
nett's T3 were used. The statistical significance level was
set at P < 0.05.
Results
cAMP and NT-3 level in transected spinal cord
Two weeks after the spinal cord surgery, the cAMP levels
in the lesion site of spinal tissue were significantly
increased in the MSCs+EA group compared to other
groups (F = 49.32, df = 3, P = 0.000), but there was no sig-
nificant difference between the Op-control group, EA
group, and MSCs group (Fig. 2A).
Four weeks following the spinal cord surgery, the NT-3
content at the lesion site in the MSCs+EA group was sig-
nificantly increased compared to the MSCs or EA groups.
However, NT-3 content at the rostral and caudal segments
of the MSCs+EA group was not significantly different from
that of the EA group. NT-3 in the Op-control group was
the lowest (Fig. 2B). Our results indicate that transplanted
MSCs and/or EA therapy may increase NT-3 level in the
spinal tissue.
Behavioral testing
After spinal cord transection, all the rats were paralyzed
and moved by pulling themselves forward with their fore-
limbs. Moreover, they presented with urinary and fecal
incontinence. The hindlimb locomotor activity of rats in
each group was evaluated by the BBB open field test at five
time points between 1 and 8 weeks post-lesion. Hindlimb
locomotor activity improved gradually in the three treat-
ment groups throughout the entire follow-up survival
period. BBB scores gradually increased over time in each
group. BBB scores were significantly higher in the three
treatment groups compared to the Op-control group in
the period from two weeks to eight weeks post-lesion (P <
0.05). However, MSCs+EA group showed a significant
higher score compared with the EA and MSCs groups after
the fourth week, most notably at the eighth week follow-
ing the operation (P < 0.01) (Fig. 3).
An alternative function test, the inclined grid test examin-
ing limb coordination, was also performed. Rats in the
MSCs+EA group voluntarily placed their paws on the grid
and pushed themselves upwards using their hindlimbs to
reach the horizontal platform. Rats in the MSCs and EA
groups placed their paws on the grid occasionally. In con-
trast, rats in the SCI group struggled to climb onto the
inclined grid with their forelimbs while their hindlimbs
dragged passively behind their body and their hind paws
often fell through the mesh. Thus, this test showed volun-
tary movement of the hindlimbs and plantar placement
primarily in the MSCs+EA group.
Spinal cord evoked potentials (SCEP)
At the end of the eighth week following spinal cord injury,
the SCEP in the Op-control group was weak, the latencies
were prolonged, and the amplitudes were significantlyBMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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decreased as compared with the other four groups (Fig.
4A, Fig. 5). However, the latencies of SCEP were signifi-
cantly shorter (Fig. 5A) and the amplitudes were increased
(Fig. 5B) in the EA+MSCs group compared to the MSCs or
EA group alone. Representative sample traces show that
SCEP stimulation normally evokes a short-latency posi-
tive-negative-positive wave, which is absent below an
acute transection of the spinal cord, and is partially
restored by EA, MSCs, or their combined treatment. Nota-
bly, this restored activity is abolished by a retransection,
which indicates descending axonal regeneration (Fig. 4B).
Survival and differentiation of MSCs in transected spinal 
cord
During the 8th week after transplantation, the grafted cells
labeled by BrdU could easily be identified with fluores-
cent microscopy, were mainly found in the lesion site, and
were well integrated with the host tissue (Fig. 6A). These
cells migrated rostrally and caudally into host tissue over
the host/lesion interface in the spinal cord. Furthermore,
statistical analyses showed that the number of surviving
MSCs in the MSCs+EA group was significantly higher than
that of the MSCs group (t = 2.861, df = 8, P < 0.05, Fig.
6B). Although most Hoechst-labeled MSCs seemed to be
clearly intact in outline, some were fragmented and
phagocytosed by ED1 immunoreactive activated macro-
phages (Fig. 6C). The ED1-labeled macrophages were still
present at the lesion site, the margins around the lesion,
cAMP and NT-3 level in the injured spinal cord Figure 2
cAMP and NT-3 level in the injured spinal cord. A. cAMP levels in the lesion tissue were measured by radioimmu-
noassay. In the MSCs+EA group, cAMP levels in the lesioned tissue were significantly higher as compared to the other groups. 
*P < 0.001. Data = means ± SD. B. NT-3 contents in the segments rostrally and caudally to the lesion site, and the lesion site 
were measured by ELISA. In all three areas, the NT-3 contents were significantly increased in the EA, MSCs, and MSCs+EA 
groups as compared to the Op-control group (* indicates P < 0.01). In the lesion site, the NT-3 contents were significantly 
higher in the MSCs+EA group than the MSCs and EA groups (# indicates P < 0.01). Moreover, the NT-3 contents in the rostral 
and caudal segments to the lesion site in the MSCs+EA group had no significant difference as compared to the Sham-control 
group (P > 0.05). Data= means ± SD.
BBB open field test: BBB scores were obtained starting from  the first week throughout the 8 week survival period (5 time  points) Figure 3
BBB open field test: BBB scores were obtained start-
ing from the first week throughout the 8 week sur-
vival period (5 time points). The scores gradually 
increased with time in each group. BBB scores were signifi-
cantly higher in the three treatment groups as compared to 
that of the Op-control group from two weeks to eight weeks 
post-transection (P < 0.05). The MSCs+EA group showed a 
significantly higher score than the other treatment groups 
beginning the 4th week following transection. Especially at 
eight weeks after the operation, the scores of the MSCs+EA 
group were significantly higher than those of the other 
groups (*indicates P < 0.01 as compared to the Op-contorl 
group; # indicates P < 0.01 compared to the EA group/MSCs 
group). Data = means ± SD.BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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and the lesion cavity in all groups, which indicated that
there was still inflammatory action in the injured spinal
cord 8 weeks after transection. A double-label immun-
ofluorescence study showed that some NF150-positive
neuron-like cells colocalized with the Hoechst-labeled
nuclei of MSCs, but not with ED1-positive activated mac-
rophages (Fig. 6D). The double-label immunostaining of
NF-150 and ED1 indirectly proved the NF-150 positive
cells in the graft site were from grafted MSCs, rather than
non-specific staining or autofluorescence of activated
macrophages.
The longitudinal spinal cord sections were examined for
differentiation markers for neuron, oligodendrocyte, and
astrocyte lineages. Fluorescent immunohistochemistry
staining revealed that transplanted MSCs were able to dif-
ferentiate into either neuron-like cells or glial-like cells.
We found that the majority of differentiated neural cells of
the engrafted MSCs were localized in the host/lesion
interfaces and the lesion site. The transplanted cells par-
tially expressed the neuronal marker, NF150 (Fig. 7A, B).
Statistical analysis indicated significantly more neuron-
like (NF150-positive) cells in the MSCs+EA group as com-
pared with the MSCs group (t = -10.296, df = 8, P < 0.001,
Fig. 7C). The percentage of differentiated neuron-like
(NF150-positive) cells is 3.18% and 5.47% in the MSCs
and MSCs+EA groups, respectively. The grafted cells par-
tially expressed the oligodendrocyte marker, MOSP,
which generally labels oligodendrocytes and central nerve
myelin, but not peripheral nerve myelin (Fig. 7D, E). Sta-
tistical analysis showed a significant difference between
the MSCs+EA (6.16%) group and the MSCs group
(2.98%) (t = -4.658, df = 8, P < 0.01, Fig. 7F). Surprisingly,
few GFAP-positive astrocytes colocalized with BrdU-
labeled MSCs.
At early stages of the transplantation process, many
grafted cells expressed nestin, a marker for neuroblast cells
(Fig. 8A). Then, some of the BrdU-labeled grafted cells
expressed β-tublin III and NF150, markers of immature
and mature neurons (Fig. 8B, Fig. 7A, B). Surprisingly, a
few BrdU-labeled MSCs co-expressed 5-HT (Fig. 8C).
Immunofluorescence double-labeling also showed some
cells co-expressed PSD95 and synapsin I in the MSCs+EA
group (Fig. 8G–I), but there were scant double-labeled
grafted cells in the MSCs group (Fig. 8D–F). Since ≥ 95%
of MSCs co-labeled with BrdU and Hoechst in vitro and in
vivo (see Additional file 2: PDF2 for the BrdU and
Hoechst co-labeling images in vitro and in vivo used to
clarify the percentage of co-labeled with BrdU and
Hoechst), we believe that Hoechst-labeled cells that co-
express PSD95 and synapsin I are grafted cells. We also
noticed that morphology of NF150, β-tubulin III, and 5-
HT positive cells differentiated from grafted MSCs were
round with few/no processes, which is not the typical
morphology of neuron-like cells. Therefore, we think that
these positive cells have neuronal phenotypes at least to
some degree, but their structures are still immature.
5-HT and CGRP fibers regeneration
Serotonergic fibers originate in brain stem nuclei, espe-
cially in the raphe nuclei, and project throughout the lon-
gitudinal extent of the spinal cord. These fibers are
thought to have a greater growth capacity following spinal
cord injury and can be conveniently detected by 5-HT
immunostaining [11,18]. In the Op-control group, 5-HT-
positive fibers grew up to the boundary of the lesion, but
did not cross the host/lesion interface into the lesion site
(Fig. 9A, a). In addition, 5-HT-positive fibers were present
in the rostral host tissue near cysts in the vicinity of the
central lesion site, and a few 5-HT-positive fibers passed
along the margins of the cysts. A few 5-HT-positive fibers
in the EA group crossed the rostral host/lesion interface
into the lesion site (Fig. 9B, b). In the MSCs group, some
5-HT-positive fibers extended into the lesion site and one
of the 5 subjects had 5-HT-positive fibers crossing the
Spinal cord evoked potential recovery after MSC transplanta- tion and EA treatment Figure 4
Spinal cord evoked potential recovery after MSC 
transplantation and EA treatment. A. The SCEPs of the 
rats in the Op-control group were very weak. After receiving 
EA, MSCs, or the combination therapy of EA and MSCs 
grafts, the SCEP of the rats recovered to different degrees. B. 
The restored activity of SCEP was abolished by a retransec-
tion, indicating descending axonal regeneration.BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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host/lesion interface into the host caudal cord. The most
caudally located axons often exhibited tortuous projec-
tions, suggesting sprouting (Fig. 9C, c). Unexpectedly, 3 of
the 7 MSCs+EA animals had visible 5-HT-positive fibers in
the host tissue caudal to the lesion site (Fig. 9D, d), and
the number of the fibers in the rostral spinal cord crossing
the rostral host/lesion interface into the lesion site were
dramatically increased in the MSCs+EA group (Fig. 9E).
CGRP-positive fibers, which label local sensory axons,
were also significantly increased in the lesion site of the
MSCs+EA group compared to both the MSCs and EA
groups (Fig. 9F–J).
Discussion
In the present study, we evaluated the effect of EA on the
survival and differentiation of MSC transplantation,
axonal regeneration, as well as functional recovery in rats
with transected spinal cords. We found that the level of
cAMP and NT-3, the number of vital and differentiated
MSCs, the number of 5-HT-positive and CGRP-positive
fibers in and near the lesion site of the injured spinal cord
were all significantly increased in the MSCs+EA group as
compared to the groups that underwent MSC transplanta-
tion or EA treatment alone. Furthermore, evidence from
BBB scales and spinal cord evoked potentials demon-
strated a significant functional recovery in the MSCs +EA
group.
MSCs transplantation combined with EA treatment
increased the cAMP level in the lesion site of the spinal
cord, which is consistent with our previous study [39].
The underlying mechanism of cAMP elevation is unclear.
However, it is possible that the pulsed electric field of EA
therapy could cause depolarization of neurons [46,47],
which would cause Ca2+ influx via L-type Ca2+ channels,
followed by Ca2+-induced elevation of intracellular cAMP
levels via Ca2+/calmodulin-dependent adenylyl cyclase
pathway [48]. Moreover, intracellular Ca2+  elevation
caused by neuronal depolarization may stimulate an
autocrine neurotrophic mechanism, leading to the syn-
thesis and release of neurotrophic factors, NT-3 and
BDNF, by the neurons themselves [49,50]. Thus, EA may
stimulate the depolarization of neurons, which causes the
opening of certain voltage-gated ion channels of neuro-
glia cells, which subsequently stimulates a rise in the
intracellular cAMP level and autocrine release of neuro-
trophic factors. cAMP elevation can increase recruitment
of the TrkB receptor to the plasma membrane of retinal
ganglion cells [51], suggesting that cAMP may promote
neuronal survival by increasing neurotrophin receptor
availability and signaling.
In previous studies, we found that EA treatment increases
the amount of NT-3 in the spinal cord tissue surrounding
the lesion site 2 weeks after spinal cord transection
The latency and amplitude of SCEP at the end of 8 weeks after MSCs transplantation and EA treatment Figure 5
The latency and amplitude of SCEP at the end of 8 weeks after MSCs transplantation and EA treatment. A. 
After spinal cord transection surgery, the latency of SCEP was significantly prolonged in Op-control group as compared with 
the Sham-control group (* indicates P < 0.05). However, the MSCs+EA group showed a significant recovery of the latency (# 
indicates P < 0.01, as compared to the Op-control group; $ indicates P < 0.05, as compared to the EA/MSCs group). B. After 
spinal cord transection surgery, the amplitude of SCEP was significantly declined in the Op-control group as compared to the 
Sham-control group (* indicates P < 0.05). However, in the MSCs, EA, or MSCs+EA group, the amplitude of SCEP was signifi-
cantly recovered as compared with the Op-control group (# indicates P < 0.05). The MSCs+EA group showed a significant 
recovery of the amplitude as compared to the EA or MSCs group ($ indicates P < 0.05). Data = means ± SD.BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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[37,39]. In addition, when studying the effects of MSC
grafts combined with EA treatment on a spinal cord
injury, we obtained similar results in which EA increased
NT-3 levels in the spinal cord tissue surrounding the
lesion site (unpublished data). These data suggest that EA
treatment may stimulate NT-3 secretion from neuroglial
cells and neurons in tissue adjacent to the lesion site. Both
our previous study and the present study show the NT-3
level 2 weeks after spinal cord transection is higher than
the level 4 weeks after transection, but the EA and
MSCs+EA groups consistently maintained higher levels of
NT-3 during this time compared to the Op-control or
MSCs groups. Interestingly, in the present study, we found
that EA combined with MSC transplantation significantly
increased the quantity of NT-3 within the lesion site as
compared to EA treatment alone. Our results also showed
that some grafted MSCs were NT-3 immunopositive cells
in the MSCs+EA group (data not shown). We propose that
increased NT-3 content in the MSCs+EA treatment group
is the result of a synergistic effect of EA treatment and MSC
transplantation, as some studies have reported that trans-
planted MSCs can produce NT-3 [24] or stimulate neuro-
glial cells to produce neurotrophic factors [52] in the
central nervous system. MSCs may also secrete cytokines
and growth factors such as NGF, BDNF, and VEGF
[23,53].
In this study, we found that the survival and differentia-
tion of MSCs into neuron-like cells and oligodendrocytes
were significantly increased in the MSCs+EA group, corre-
sponding to a similar elevation in NT-3 and cAMP levels.
This data suggests that EA promotes the survival and dif-
The survival and differentiation of MSCs in the injured spinal  cord Figure 6
The survival and differentiation of MSCs in the 
injured spinal cord. A. BrdU-labeled nuclei (green) of 
MSCs in the injured spinal cord in the MSCs+EA group. 
Grafted BrdU-labeled MSCs were well integrated with host 
tissue and migrated into host tissue over the host/lesion 
interface in the spinal cord both rostrally and caudally. Two 
broken lines outline the lesion site. Inset in A showing the 
BrdU-labeled MSCs – at a higher magnification (Scale bars: 80 
μm; Insets, 20 μm.). B. The number of survived MSCs in the 
lesion site (MSCs+EA vs. MSCs, * indicates P < 0.05). Data = 
means ± SD. C. ED1-immunostained activated macrophages 
(red) in the lesion site; numerous grafted MSCs (Hoechst 
labeled the nuclei of MSCs, blue) survived in the lesion site, 
some were phagocytosed by ED1 immunoreactive activated 
macrophages (arrowheads). D. NF150-positive neuron-like 
cells (green, arrows) co-localized with Hoechst-labeled 
nuclei of MSCs (Hoechst, blue), but not with ED1-positive 
activated macrophages (red). Scale bars: A = 80 μm, C and D 
= 20 μm.
Differentiation of MSCs into neuron-like and oligodendro- cyte-like cells at 8 weeks following transplantation Figure 7
Differentiation of MSCs into neuron-like and oli-
godendrocyte-like cells at 8 weeks following trans-
plantation. A and B: NF150 (red) and BrdU (green) double-
labeling show the NF150-positive neuron-like cells (arrows) 
in the MSCs group (A) and MSCs+EA (B) group. Cell number 
counting indicates the number of NF150/BrdU double-
labeled cells was significantly higher in the MSCs+EA group 
compared to the MSCs group (C, * indicates P < 0.05). D and 
E: MOSP (red) and BrdU (green) double-labeling show the 
MOSP-positive oligodendrocyte-like cells (arrows) in the 
MSCs group (D) and MSCs+EA group (E). Cell number 
counting indicates the number of MOSP/BrdU double-labeled 
cells was significantly higher in the MSCs+EA group as com-
pared to the MSCs group (F, * indicates P < 0.05). Data= 
means ± SD. Scale bars: A, B, D, E = 20 μm.BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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ferentiation of grafted MSCs by elevating neurotrophic
factors (such as NT-3) and the level of cAMP in injured
spinal cord tissue. NT-3 is a significant member of the
neurotrophic factors family and plays an important role
during nervous system development, neuronal survival
and differentiation, and neuronal repair via a signal trans-
duction pathway [54]. In particular, NT-3 can induce both
the survival and proliferation of oligodendrocytes by dif-
ferential involvement of the transcription factor CREB
[55,56]. In vivo studies of animal models have suggested
that NT-3 may play an important role in regulating the
quantity of oligodendrocytes and myelin regeneration fol-
lowing a CNS injury and demyelination [51,57]. In addi-
tion, some studies have demonstrated that cAMP provides
a powerful survival signal for neurons [42,58].
However, several observations have raised questions
regarding neuronal transdifferentiation of MSCs and sug-
gested that the transdifferentiation was attributed to cell
fusion with host cells. Several laboratories have proposed
that MSCs fuse with the host cells, including the neurons,
and acquire their phenotypes, which simulate their
transdifferentiation into host cells [59-62]. While cell
fusion could explain a good fraction of this apparent neu-
ral transdifferentiation of transplanted MSCs, there con-
tinues to be new evidence to suggest that, at least in some
particular experimental paradigms, transdifferentiation
does indeed occur [63-65]. Munoz-Elias et al. [64] trans-
planted adult rat bone marrow stromal cells into embry-
onic brains and observed that donor cells entered
ventricular germinal zones, expressed neural progenitor
traits, migrated to distant brain regions, and expressed
site-specific neuronal proteins without cell fusion phe-
Differentiation of MSCs into neuron-like cells at 8 weeks fol- lowing transplantation Figure 8
Differentiation of MSCs into neuron-like cells at 8 
weeks following transplantation. A, B and C: Using dif-
ferent makers (nestin for neuroblast cells (A), β-tublin III for 
young neurons (B), and 5-HT for functional neurons (C) 
combined with a BrdU double-label), we found that MSCs 
transplanted into injured spinal cord tissue could survive and 
differentiate into neuronal phenotypes in the MSCs+EA 
group. D-F: In the MSCs group, a double immunofluores-
cence study of PSD95 (green) and synapsin I (red) showed a 
small number of coexpressing cells. G-I: Double immunofluo-
rescence showed that some cells coexpressed PSD95 
(green) and synapsin I (red) in the grafts of the EA+MSCs 
group. Scale bars: 20 μm.
5-HT and CGRP-positive nerve fibers in the injured spinal  cord at 8 weeks following surgery Figure 9
5-HT and CGRP-positive nerve fibers in the injured 
spinal cord at 8 weeks following surgery. A-D: A longi-
tudinal section of spinal cord shows 5-HT positive fibers in 
the Op-control group (A), EA group (B), MSCs group (C), 
and MSCs+EA group (D). a-d: Higher magnification of the 
rectangle boxes in Fig. A-D. Scale bars: A, B, C, D = 320 μm; 
a, b, c, d = 40 μm. E: Comparison of the number of 5-HT 
positive fibers in the lesion site and the region immediately 
rostral to the lesion site among the 4 groups (MSCs+EA vs. 
Op-control group, * indicates P < 0.01; MSCs+EA vs. MSCs 
or EA groups: # indicates P < 0.05). F-I: A longitudinal sec-
tion of spinal cord shows CGRP-positive fibers (arrows) in 
the Op-control group (F), EA group (G), MSCs group (H), 
and MSCs+EA group (I). Scale bars: F, G, H, I = 20 μm. 
J:Comparison of the number of CGRP-positive fibers located 
in the lesion site in the 4 groups (MSCs+EA vs. Op-control 
group, *indicates P < 0.001; MSCs+EA vs. EA or MSCs 
groups, # indicates P < 0.001).BMC Neuroscience 2009, 10:35 http://www.biomedcentral.com/1471-2202/10/35
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nomena. Recently, Hokari et al. [66] found that bone mar-
row stromal cells might have the potential not only to
differentiate into neurons, but also may fuse spontane-
ously with host neurons within 24 hr of cell-mixing coc-
ulture commencement. However, we never observed
multiple nuclei originating from MSCs in the double-
labeled cells during our study. Additionally, the NF150, β-
tublin III, and 5-HT positive cells differentiated from
grafted MSCs had few/no processes, which is not the typ-
ical morphology of host neurons. Furthermore, previous
studies have suggested that this fusion is a rare event
[59,60]. Thus, we believe MSC-derived neuron-pheno-
typic cells were mostly transdifferentiated from donor
cells, although we could not absolutely rule out host cell
fusion. In addition, we found that the MSCs+EA group
had more double-labeled neuron-phenotypic cells from
MSCs than the MSCs group. We are not clear whether EA
promotes grafted MSCs to transdifferentiate or fuse with
host cells, so we will further study the effect of EA on the
fate of grafted MSCs in the future.
We also found that 5-HT and CGRP-positive immunos-
tained axons were regenerated in or across the lesion site
into the caudal spinal cord at different degrees, most
prominently in the MSCs combined with EA treatment
group. It is known that scar formation by glia prolifera-
tion, lack of tropic support and inhibitory molecules [67]
are key factors that block axons from regenerating into the
injured spinal cord. However, several studies indicate that
EA treatment can increase the tissue cAMP level and the
expression of neurotrophic factors, such as NT-3, BDNF,
NGF, and GDNF [68,69]. Similarly, several studies
[70,71] have demonstrated that MSCs also secrete a vari-
ety of growth factors and cytokines, which can promote
axonal growth in vitro as well as in vivo [43,72,73]. In
addition, Yang et al. reported that EA treatment can
inhibit the reactive proliferation of astrocytes after spinal
cord injury and prevent the formation of a glial scar [74].
Therefore, combining MSC transplantation and EA treat-
ment may synergistically modify the hostile environment
in the lesion site to promote axonal regrowth by increas-
ing the amount of neurotrophic factors and the cAMP
level and inhibiting glia scar formation.
The detection and behavioral analysis of spinal cord
evoked potentials suggest that MSC transplantation com-
bined with EA treatment efficiently improves neuronal
function recovery. MSCs transdifferentiate into neurons
and oligodendrocytes to replace the damaged or dead
neural cells or repair myelin sheaths in the injured spinal
cord, and increase the number of 5-HT-fibers passing
through the lesion site into the caudal spinal tissue, which
may be the morphological basis of the functional out-
comes. However, whether or not these "neural cells" neu-
rons were in fact functionally replaced damaged spinal
cord neurons needs to be confirmed.
Conclusion
In summary, our experiments have shown that MSC trans-
plantation combined with EA treatment promotes MSC
survival and differentiation into neural-like cells, stimu-
lates axonal growth into the lesion/transplant site, and
improves hindlimb locomotion. Increased NT-3 and
cAMP levels in the injured/transplanted area may be the
main molecular mechanism of the morphological and
functional effects of the treatment. Our results suggest a
new therapeutic potential of the combination of MSC
transplantation with EA treatment to treat spinal cord
injury patients.
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was about 95% in vitro. B. Hoechst-labeled nuclei (blue, arrows) in the 
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